Global clinical trial identifies safer and equally effective antibiotics for staphylococcal bloodstream infections

A landmark international clinical trial, the SNAP Trial, has found that the standard antibiotic, cloxacillin (or flucloxacillin), should no longer be the primary choice for treating golden staph (Staphylococcus aureus) bloodstream infections. The study, published simultaneously in the New England Journal of Medicine (NEJM) and The Lancet, revealed that cefazolin and benzylpenicillin offer safer and equally effective alternatives, with fewer side effects and a lower risk of kidney injury.